Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APRESOLINE-ESIDRIX vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Apresoline (hydralazine) is a direct-acting vasodilator that relaxes arteriolar smooth muscle via unknown mechanism; Esidrix (hydrochlorothiazide) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension
Hypertension
Hydralazine (Apresoline): Oral, initial 10 mg 4 times daily for first 2-4 days, then increase to 25 mg 4 times daily for first week, then 50 mg 4 times daily thereafter. Maximum daily dose: 300 mg. Hydrochlorothiazide (Esidrix): Oral, initial 12.5-25 mg once daily, may increase to 50 mg once daily if needed.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Hydralazine: 2-8 h (prolonged in renal impairment); Hydrochlorothiazide: 6-15 h (mean 10 h, increased in renal failure).
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Hydralazine undergoes N-acetylation (polymorphic, NAT2) and CYP450; hydrochlorothiazide is not extensively metabolized (excreted unchanged in urine).
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal: Hydralazine 85-90% as metabolites, 5-10% unchanged; Hydrochlorothiazide 95% as unchanged drug. Biliary/fecal: Hydralazine <10%.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Hydralazine: 85-90% (primarily albumin); Hydrochlorothiazide: 40-68% (albumin).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Hydralazine: 1.5-1.8 L/kg (extensive tissue distribution); Hydrochlorothiazide: 0.83-1.2 L/kg.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Hydralazine: 30-50% (oral, extensive first-pass metabolism; slower in slow acetylators); Hydrochlorothiazide: 65-75% (oral).
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Hydralazine: No adjustment for GFR >10 m L/min; for GFR <10 m L/min, reduce dose to 30-50% of normal. Hydrochlorothiazide: Not effective if GFR <30 m L/min; use alternative diuretic. For Cr Cl 30-50 m L/min, reduce dose or interval.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Hydralazine: Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. Hydrochlorothiazide: Caution in severe liver disease due to electrolyte imbalances; no specific dose adjustment defined; use with monitoring.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Hydralazine: Oral, initial 0.75-1 mg/kg/day in 2-4 divided doses, increase over 3-4 weeks to maximum 7.5 mg/kg/day or 200 mg/day. Hydrochlorothiazide: Oral, 1-2 mg/kg/day in 2 divided doses; maximum 6 mg/kg/day or 50 mg/day.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Hydralazine: Start at lower end of dosing range (10 mg 4 times daily) and titrate slowly due to increased sensitivity and risk of hypotension. Hydrochlorothiazide: Start at 12.5 mg once daily, monitor renal function and electrolytes more frequently.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
No black box warning specifically for the combination; hydralazine carries a warning for drug-induced lupus erythematosus.
None.
Lupus erythematosus-like syndrome (hydralazine),Hypotension,Myocardial infarction (exacerbation due to reflex tachycardia),Electrolyte imbalances (hypokalemia, hyponatremia) from thiazide,Hyperuricemia,Sulfonamide allergy cross-reactivity (thiazide)
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to hydralazine or hydrochlorothiazide,Anuria,Concomitant use with MAO inhibitors,Rheumatic mitral valve disease (hydralazine)
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid natural licorice (glycyrrhizin) as it can worsen hypokalemia and reduce antihypertensive effect. High-sodium foods should be limited as they can counteract the blood pressure-lowering effect. Grapefruit juice may enhance hydralazine absorption; consistent consumption is advised if intake is routine. Alcohol may potentiate orthostatic hypotension and dizziness.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
APRESOLINE-ESIDRIX (hydralazine/hydrochlorothiazide). First trimester: Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions. Hydralazine has been associated with minor anomalies in animal studies but no well-controlled human studies; risk cannot be ruled out. Second/third trimester: Maternal hypotension may reduce uterine blood flow; HCTZ may cause fetal electrolyte disturbances, thrombocytopenia, and jaundice. Avoid use for edema in pregnancy; use only if clearly needed.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Hydralazine: M/P ratio unknown; excreted in breast milk in small amounts; unlikely to cause adverse effects in infant. Hydrochlorothiazide: M/P ratio ~0.3; excreted in breast milk; may suppress lactation; use caution, especially if high doses or dehydration.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Dose adjustments not typically required; however, pregnancy may alter pharmacokinetics (increased volume of distribution, increased renal clearance). Use lowest effective dose; monitor response. Avoid HCTZ for routine edema; use only if other diuretics contraindicated. Start with low doses and titrate slowly.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
APRESOLINE-ESIDRIX is a fixed-dose combination of hydralazine (vasodilator) and hydrochlorothiazide (thiazide diuretic). Monitor for reflex tachycardia and fluid retention with hydralazine; hypokalemia, hyponatremia, and hyperuricemia with hydrochlorothiazide. Use with caution in severe renal impairment (Cr Cl <30 m L/min) and coronary artery disease. May cause lupus-like syndrome with prolonged high-dose hydralazine (usually >200 mg/day). Administer with food to reduce GI upset.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,You may experience dizziness or lightheadedness, especially when standing up quickly; rise slowly from sitting or lying down.,Report any unexplained joint pain, rash, fever, or fatigue, as these may be signs of a lupus-like reaction.,Avoid alcohol, which can increase blood pressure-lowering effects and dizziness.,Drink adequate fluids unless otherwise advised by your doctor, but do not increase salt intake without consulting your healthcare provider.,Do not stop taking this medication abruptly, as sudden withdrawal may cause a rapid increase in blood pressure.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APRESOLINE-ESIDRIX vs ALDOCLOR-150, answered by our medical review team.
APRESOLINE-ESIDRIX is a Antihypertensive that works by Apresoline (hydralazine) is a direct-acting vasodilator that relaxes arteriolar smooth muscle via unknown mechanism; Esidrix (hydrochlorothiazide) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APRESOLINE-ESIDRIX and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APRESOLINE-ESIDRIX is: Hydralazine (Apresoline): Oral, initial 10 mg 4 times daily for first 2-4 days, then increase to 25 mg 4 times daily for first week, then 50 mg 4 times daily thereafter. Maximum daily dose: 300 mg. Hydrochlorothiazide (Esidrix): Oral, initial 12.5-25 mg once daily, may increase to 50 mg once daily if needed.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APRESOLINE-ESIDRIX and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APRESOLINE-ESIDRIX is classified as Category C. APRESOLINE-ESIDRIX (hydralazine/hydrochlorothiazide). First trimester: Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.